4.04
4.04 (0%)
As of Apr 17, 2025
Checkpoint Therapeutics, Inc. [CKPT]
Source:
Company Overview
Checkpoint Therapeutics, Inc is a commercial-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers.
| Country | United States |
| Headquarters | waltham, massachusetts |
| Phone Number | (781) 652-4500 |
| Industry | manufacturing |
| CEO | James F. Oliviero |
| Website | www.checkpointtx.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $0 |
| Operating Profit | $-56.2 |
| Net Income | $-56.2 |
| Net Cash | $1.7 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | -137,009.8 |
| Profit as % of Revenues | -0.1% |
| Profit as % of Assets | -875.4% |
| Profit as % of Stockholder Equity | 445.5% |
Management Effectiveness
| Return on Equity | 445.5% |
| Return on Assets | -752.8% |
| Turnover Ratio | 0.6% |
| EBITA | $-56.2 |
Balance Sheet and Cash Flow Measures
| Total Assets | $7.5 |
| Total Liabilities | $20.1 |
| Operating Cash Flow | $-31.1 |
| Investing Cash Flow | |
| Financing Cash Flow | $32.8 |
